Dr Ferdy van Geest, (Erasmus Medical Center, Rotterdam, The Netherlands) kindly spoke with us about the results of his study investigating Triac in patients with MCT8.
The abstract entitled ‘Long-term efficacy of triiodothyronine analogue Triac in children and adults with monocarboxylate transporter 8 deficiency: an international, real-life cohort study’ (Abstract 82) was given at European Thyroid Association (ETA) Annual Meeting 2021, 4–7 September.
1. What clinical characteristics do patients with monocarboxylate transporter MCT8 deficiency display? (0:35)
2. Please describe the mechanism of action of Triac and what has been previously established regarding efficacy and safety in patients with MCT8 deficiency? (2:19)
3. What further evidence did this real-life cohort study aim to gather? (4:02)
4. What were the key results of the study? (6:06)
5. How will Triac impact the treatment of patients with MCT8 deficiency? (7:06)
Disclosures: The Erasmus Medical Center (Rotterdam, Netherlands), which employs FSvG, receives royalties from Rare Thyroid Therapeutics (the manufacturer of Triac), dependent on commercialization. None of the authors will benefit personally from any royalties. Rare Thyroid Therapeutics had no influence on the conduct or analysis of this study.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Louise Taylor.
Filmed in coverage of the European Thyroid Association (ETA) Annual Meeting 2021, 4–7 September 2021.
van Geest F, Groeneweg S, van Toor H, et al. 82: Long-term efficacy of triiodothyronine analogue Triac in children and adults with monocarboxylate transporter 8 deficiency: an international, real-life cohort study. Eur Thyroid J 2021;10(Suppl. 1):6.
Share this Video
Related Videos In Thyroid Disorders
Sina Jasim, ENDO23: Cytologic and Molecular Assessment of Isthmus Thyroid Nodules
Thyroid nodules arising in the isthmus are more likely to be malignant and demonstrate more aggressive behavior relative to thyroid nodules from either thyroid lobe. touchENDOCRINOLOGY were joined by Dr Sina Jasim (Washington University, St Louis, MO, USA) to discuss the main findings of her study presented at ENDO23. The abstract ‘THU-680 – Cytologic And […]
Updated guidelines for the management of primary hyperparathyroidism: Aliya Khan, WCO-IOF-ESCEO 2023
Surgery remains a mainstay of treatment in primary hyperparathyroidism (PHPT), the new guidelines for management provide alternative options for patients in which surgery is contraindicated. We were delighted to speak to Prof. Aliya A. Khan (McMaster University Medical Centre, Hamilton, Canada) around the current management of PHPT, the updates to management in the new guidelines […]
Symptoms, diagnosis and complications in primary hyperparathyroidism: Aliya Khan, WCO-IOF-ESCEO 2023
Primary hyperparathyroidism (PHPT) is caused by the overproduction of parathyroid hormone (PTH) by the parathyroid gland, the symptoms of which can remain dormant until later in life and as such PHPT is often underdiagnosed. We were delighted to speak to Prof. Aliya A. Khan (McMaster University Medical Centre, Hamilton, Canada) around the presentation of PHPT, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!